Targeted Therapy and Immunotherapy: Diamonds in the Rough in the Treatment of Epithelial Ovarian Cancer

Overview

Journal Front Pharmacol

Date 2023 Apr 10

PMID 37033645

Authors

Xu Huang

Xiao-Yu Li

Wu-Lin Shan

Yao Chen

Qi Zhu

Bai-Rong Xia

Affiliations

Soon will be listed here.

Abstract

Currently, for ovarian cancer, which has the highest mortality rate among all gynecological cancers, the standard treatment protocol is initial tumor cytoreductive surgery followed by platinum-based combination chemotherapy. Although the survival rate after standard treatment has improved, the therapeutic effect of traditional chemotherapy is very limited due to problems such as resistance to platinum-based drugs and recurrence. With the advent of the precision medicine era, molecular targeted therapy has gradually entered clinicians' view, and individualized precision therapy has been realized, surpassing the limitations of traditional therapy. The detection of genetic mutations affecting treatment, especially breast cancer susceptibility gene (BRCA) mutations and mutations of other homologous recombination repair defect (HRD) genes, can guide the targeted drug treatment of patients, effectively improve the treatment effect and achieve a better patient prognosis. This article reviews different sites and pathways of targeted therapy, including angiogenesis, cell cycle and DNA repair, and immune and metabolic pathways, and the latest research progress from preclinical and clinical trials related to ovarian cancer therapy.

Citing Articles

Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer.

Philips T, Erickson B, Thomas S Front Oncol. 2025; 14():1503107.

PMID: 39839766 PMC: 11746003. DOI: 10.3389/fonc.2024.1503107.

Targeted radiopharmaceuticals: an underexplored strategy for ovarian cancer.

Crabbe M, Opsomer T, Vermeulen K, Ooms M, Segers C Theranostics. 2024; 14(16):6281-6300.

PMID: 39431018 PMC: 11488094. DOI: 10.7150/thno.99782.

Recombinant humanized type III collagen inhibits ovarian cancer and induces protective anti-tumor immunity by regulating autophagy through GSTP1.

Zeng H, Li H, Wang L, You S, Liu S, Dong X Mater Today Bio. 2024; 28:101220.

PMID: 39290464 PMC: 11405829. DOI: 10.1016/j.mtbio.2024.101220.

Nuclear receptors in ovarian cancer: changing paradigms in cancer therapeutics.

Sajeev A, BharathwajChetty B, Manickasamy M, AlQahtani M, Abbas M, Shakibaei M Front Oncol. 2024; 14:1383939.

PMID: 39077471 PMC: 11284039. DOI: 10.3389/fonc.2024.1383939.

Bevacizumab-Based Therapies in Malignant Tumors-Real-World Data on Effectiveness, Safety, and Cost.

Chitoran E, Rotaru V, Ionescu S, Gelal A, Capsa C, Bohiltea R Cancers (Basel). 2024; 16(14).

PMID: 39061228 PMC: 11274419. DOI: 10.3390/cancers16142590.

References

ODonnell D . Rucaparib for BRCA1/2-mutated pretreated ovarian cancer: reflections from the ARIEL4 trial. Lancet Oncol. 2022; 23(4):440-441. DOI: 10.1016/S1470-2045(22)00150-4. View

Munn D, Mellor A . IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol. 2016; 37(3):193-207. PMC: 4916957. DOI: 10.1016/j.it.2016.01.002. View

Xiong Y, Guo Y, Liu Y, Wang H, Gong W, Liu Y . Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor. Neoplasia. 2020; 22(9):431-440. PMC: 7350150. DOI: 10.1016/j.neo.2020.06.009. View

Mirza M, Pignata S, Ledermann J . Latest clinical evidence and further development of PARP inhibitors in ovarian cancer. Ann Oncol. 2018; 29(6):1366-1376. DOI: 10.1093/annonc/mdy174. View

An Y, Yang Q . MiR-21 modulates the polarization of macrophages and increases the effects of M2 macrophages on promoting the chemoresistance of ovarian cancer. Life Sci. 2019; 242:117162. DOI: 10.1016/j.lfs.2019.117162. View

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

Lu Y, Chu A, Turker M, Glazer P . Hypoxia-induced epigenetic regulation and silencing of the BRCA1 promoter. Mol Cell Biol. 2011; 31(16):3339-50. PMC: 3147797. DOI: 10.1128/MCB.01121-10. View

Sisay M, Edessa D . PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers. Gynecol Oncol Res Pract. 2017; 4:18. PMC: 5706442. DOI: 10.1186/s40661-017-0055-8. View

Matulonis U, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C . Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009; 27(33):5601-6. PMC: 2792954. DOI: 10.1200/JCO.2009.23.2777. View

10.

Rob L, Cibula D, Knapp P, Mallmann P, Klat J, Minar L . Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. J Immunother Cancer. 2022; 10(1). PMC: 8739446. DOI: 10.1136/jitc-2021-003190. View

11.

van Vloten J, Matuszewska K, Minow M, Minott J, Santry L, Pereira M . Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer. J Immunother Cancer. 2022; 10(3). PMC: 8928368. DOI: 10.1136/jitc-2021-004335. View

12.

Clamp A, Lorusso D, Oza A, Aghajanian C, Oaknin A, Dean A . Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. Int J Gynecol Cancer. 2021; 31(7):949-958. PMC: 9445915. DOI: 10.1136/ijgc-2020-002240. View

13.

Kobel M, Madore J, Ramus S, Clarke B, Pharoah P, Deen S . Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. Br J Cancer. 2014; 111(12):2297-307. PMC: 4264456. DOI: 10.1038/bjc.2014.567. View

14.

Chen L, Cheng X, Tu W, Qi Z, Li H, Liu F . Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells. Cell Oncol (Dordr). 2019; 42(5):679-690. DOI: 10.1007/s13402-019-00455-x. View

15.

Ledermann J, Oza A, Lorusso D, Aghajanian C, Oaknin A, Dean A . Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020; 21(5):710-722. PMC: 8210534. DOI: 10.1016/S1470-2045(20)30061-9. View

16.

Moore K, Oza A, Colombo N, Oaknin A, Scambia G, Lorusso D . Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021; 32(6):757-765. DOI: 10.1016/j.annonc.2021.02.017. View

17.

Lan C, Zhao J, Yang F, Xiong Y, Li R, Huang Y . Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial. Cell Rep Med. 2022; 3(7):100689. PMC: 9381412. DOI: 10.1016/j.xcrm.2022.100689. View

18.

Tanyi J, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R . Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018; 10(436). DOI: 10.1126/scitranslmed.aao5931. View

19.

Del Campo J, Matulonis U, Malander S, Provencher D, Mahner S, Follana P . Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. J Clin Oncol. 2019; 37(32):2968-2973. PMC: 6839909. DOI: 10.1200/JCO.18.02238. View

20.

Sjoquist K, Espinoza D, Mileshkin L, Ananda S, Shannon C, Yip S . REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer. Gynecol Oncol. 2021; 161(2):374-381. DOI: 10.1016/j.ygyno.2021.02.002. View